Nuclear factor kappaB/p49 is a negative regulatory factor in nerve growth factor-induced choline acetyltransferase promoter activity in PC12 cells.
Anovel nuclear factor kappaB (NF-kappaB) binding site has been identified within the promoter region of the mouse gene encoding choline acetyltransferase (ChAT), the enzyme that synthesizes acetylcholine and has been implicated in the cognitive deficits associated with aging and Alzheimer's disease. This binding site, which is located within the nerve growth factor (NGF)-responsive enhancer element, was recognized by the NF-kappaB protein p49 but not p65 or p50. p49 from both basal forebrain and PC12 nuclear extracts interacted with this specific sequence in electrophoretic mobility shift assays. Mutation of the NF-kappaB site caused an increase in NGF-induced promoter activation, whereas overexpression of p49 in NGF-differentiated PC12 cells caused a decrease in endogenous ChAT enzyme activity and a decrease in promoter activity that was specifically mediated through this NF-kappaB binding site. Treatment of PC12 cells with NGF resulted in a drastic reduction in nuclear p49 binding to the ChAT NF-kappaB site after 24 h, but nuclear p49 levels were not altered, suggesting that late NGF-mediated events prevent binding of p49 to the ChAT promoter by an unknown mechanism other than nuclear translocation. Decreased ChAT expression and increased NF-kappaB activity in the brain are associated with aging and Alzheimer's disease. These data indicate that p49 is a negative regulator of ChAT expression and suggest a possible mechanism for aging-associated declines in cholinergic function.
Toliver-Kinsky
T
T
Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas 77555-0652, USA. ttoliver@email.utmb.edu
Wood
T
T
Perez-Polo
J R
JR
D000375:Aging / Q000378:metabolism; D000544:Alzheimer Disease / Q000378:metabolism*; D000828:Animal Population Groups; D000818:Animals; D001665:Binding Sites / Q000235:genetics; D001923:Brain Chemistry; D002460:Cell Line; D002795:Choline O-Acetyltransferase / Q000096:biosynthesis / Q000235:genetics*; D018983:DNA Footprinting; D004742:Enhancer Elements, Genetic / Q000187:drug effects; D008297:Male; D016297:Mutagenesis, Site-Directed; D016328:NF-kappa B / Q000378:metabolism*; D020932:Nerve Growth Factor / Q000378:metabolism* / Q000494:pharmacology; D009687:Nuclear Proteins / Q000378:metabolism; D016716:PC12 Cells; D011401:Promoter Regions, Genetic; D016548:Prosencephalon / Q000737:chemistry / Q000378:metabolism; D020033:Protein Isoforms / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D016328:NF-kappa B; D009687:Nuclear Proteins; D020033:Protein Isoforms; D020932:Nerve Growth Factor; D002795:Choline O-Acetyltransferase